FIND A DOCTOR1-800-CEDARS-1
Available 24 Hours a Day
8 a.m.-5 p.m.
Samuel Oschin Comprehensive Cancer Institute
Kidney cancer, also known as renal cell carcinoma, is curable when detected before it has spread. Hyung Lae Kim, MD, Associate Director for Surgical Research at the Samuel Oschin Comprehensive Cancer Institute, and his team, conduct research to evaluate the best ways to diagnose and treat renal cell carcinoma. Management strategies include:
The goals of the clinical research are to prevent death from kidney cancer, minimize the morbidity of surgery by using laparoscopic and robotic techniques, and preserve as much kidney function as possible during surgery.
Another area of research at Cedars-Sinai involves investigating molecular biomarkers that can help identify the most aggressive forms of kidney cancer. This research may some day allow physicians to identify patients who can be managed without surgery, patients who need aggressive surgery, and patients who need early chemotherapy.
Ongoing laboratory research at Cedars-Sinai is attempting to identify new therapies that stimulate the body's own immune system to attack kidney cancer.
Hellenthal, N.J., Underwood, W., Penetrante, R., Litwin, A., Zhang, S., Teh, B.T., Kim, H.L., Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J Urol September 2010, Volume 184(3): 859-64 (Click here for the
related to this article)
Blumenfeld, A.J., Guru, K.A., Kim, H.L., Percutaneous biopsy of renal cell carcinoma underestimates nuclear grade. Urology 2010 March 75.
Shah, S.K., Matin, S.F., Singer, E.A., Eichel, L., Kim, H.L., Outcomes of Laparoscopic Partial Nephrectomy after Fellowship Training. JSLS 2009 April; 13(2):154-9.
Kim, H.L., Shah, S.K., Tan, W., Shikanov, S.A., Zorn, K.C., Shalhav, A.L., Wilding, G.E., Estimation and Prediction of Renal Function in Patients with Renal Tumor. J Urol 2009 Apr; 181(6): 2451-60.
Shah, S., Chapman, T., Kim, H.L., Cold scissors dissection and simplified repair for partial nephrectomies. Urology Times Clinical Edition. March 1, 2009: S10-14.
Gore, J., Kim, H.L., Schulam, P., Initial experience with laparoscopically-assisted percutaneous cryotherapy of renal tumors. J of Endourol, 2005; 19(4): 480-483.
Glenn, S.T., Head, KL., Teh, B.T., Gross, K.W., Kim, H.L., Maximizing RNA yield from archival renal tumors and optimizing gene expression analysis. J Biomol Screen 2010 Jan 15(1):80-5.
Nogueira, M., and Kim, H.L., Molecular Markers for Predicting Prognosis of Renal Cell Carcinoma. Urol Oncol 2008 March; 26:113-124.
Glenn, S.T., Jones, C.A., Liang, P., Kaushik, D., Gross, K. W., Kim, H.L., Expression profiling of archival renal tumors by quantitative PCR to validate prognostic markers. Biotechniques 2007 November; 43(5):639-647.
Yang, X., Tan, M. H., Kim, H.L., Ditlev, J.A., Betten, M.W., Png, C.E., Kort, E.J., Futami, K., Furge, K.A., Takahashi, M., Kanayama, H.O., Tan, P.H., Teh, B.X., Luan, C., Wang, K., Pins, M., Tretiakova, M.S., Anema, J.G., Kahnoski, R.J., Nicol, T.L., Stadler, W.M., Vogelzang, N. J., Amato, R., Seligson, D., Figlin, R.A., Belldegrun, A.S., Rogers, C.G., Ten, B., The A molecular classification of papillary renal cell carcinoma. Cancer Res, 2005; 65(13):5628-5637.
Kim, H.L., Seligson, D., Liu, X., Janzen, N., Bui, M., Yu, H., Tao, S., Figlin, R.A., Horvath, S., Belldegrun, A.S., Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res, 2004; 10: 5464-5471.
Yi, H., Yu, X., Gao, P., Wang, Y., Kim, H.L., Subjeck, J.R., and Wang, X.Y., Pattern recognition scavenger receptor SRA/CD204 down-regulates TLR4 signaling dependent CD8 T-cell activation. Blood 2009 Jun 4;113(23):5819-28
Wang, Y., Wang, X.Y., Subjeck, J., Kim, H.L., Carbonic Anhydrase IX has Chaperone-like Functions and is an Immunoadjuvant. Mol Cancer Ther, 2008 December; 7(12):3867-3877.
Kim, H.L., Sun, X., Subjeck, J.R., Wang X.Y., W., Evaluation of renal cell carcinoma vaccines targeting carbonic anhydrase IX using heat shock protein 110. Cancer Immunol Immunother 2007 July;56(7):1097-105.